Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
HS&M Magazine
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
IPI-549
HSMN NewsFeed - 22 Aug 2019
Erasca Announces Key Leadership Team Appointments and Recruits World-Class Research and Development Advisory Board
Biopharmaceuticals
Oncology
Personnel
HSMN NewsFeed - 6 May 2019
FogPharma Strengthens New Modality Drug Hunting Team with Appointment of Howard Stern as Chief Scientific Officer and Peter Fekkes as Vice President of Discovery Bioscience
Biopharmaceuticals
Personnel
HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Biopharmaceuticals
Oncology
Personnel
HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals
Oncology
Personnel
HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals
Oncology
Licensing
HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals
Acquisitions
Return to NewsFeed
